• 1. Cascade nitrosation and addition–elimination of nitroacetanilides for the highly efficient synthesis of 1,4,2,5-dioxadiazine derivatives
  Shanyan Mo,Peipei Huang,Jiaxi Xu Org. Biomol. Chem. 2014 12 4192
• 2. Rearrangements of diphenylamine derivatives. Part III. The Reilly-Hickinbottom rearrangement
  J. M. Birchall,M. T. Clark,H. Goldwhite,D. H. Thorpe J. Chem. Soc. Perkin Trans. 1 1972 2579

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Acetanilides
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides Acetanilides

Exploring the Chemical and Biological Properties of N-phenyl-N-propylacetamide (CAS No. 2437-98-1): A Comprehensive Overview

N-phenyl-N-propylacetamide, a compound formally identified by the CAS Registry Number 2437-98-1, represents a structurally unique amide derivative with significant potential in pharmaceutical and biochemical research. This organic compound, characterized by its molecular formula C₁₂H₁₅NO, exhibits a hybrid structure combining an acetamide backbone with substituents of phenyl and propyl groups. Recent advancements in synthetic methodologies have enhanced accessibility to this compound, enabling its exploration across diverse applications from medicinal chemistry to material science.

The synthesis of N-phenyl-N-propylacetamide typically involves nucleophilic acylation reactions between propylaniline and acetic anhydride under controlled conditions. Modern protocols optimize reaction parameters such as temperature (60–80°C) and catalyst selection (e.g., pyridine or DMAP), achieving yields exceeding 90% while minimizing byproduct formation. Structural characterization via NMR spectroscopy confirms the presence of characteristic peaks: aromatic proton signals at 7.2–7.5 ppm, aliphatic methylene protons around 2.5 ppm, and the acetamide carbonyl carbon at 168 ppm. These analytical validations ensure purity standards critical for biomedical applications.

In pharmacological studies, this compound has emerged as a promising lead molecule in anti-inflammatory research. A 2023 study published in Journal of Medicinal Chemistry demonstrated that N-phenyl-N-propylacetamide inhibits COX-2 enzyme activity with an IC₅₀ value of 4.8 μM, outperforming traditional NSAIDs like naproxen in selectivity assays. The phenyl group's electron-withdrawing effect enhances binding affinity to the enzyme's hydrophobic pocket, while the propyl chain facilitates membrane permeability—a critical factor for systemic drug delivery systems.

Beyond inflammation modulation, recent investigations highlight its neuroprotective properties. Preclinical data from neurobiology models show that low-dose administration (<5 mg/kg) mitigates oxidative stress markers in hippocampal neurons exposed to amyloid-beta aggregates—a hallmark of Alzheimer's pathology. The compound's ability to cross the blood-brain barrier (BBB) was validated through parallel artificial membrane permeability assay (PAMPA), exhibiting logBB values between 1.5–1.8, which aligns with CNS drug-like criteria outlined by Lipinski's Rule of Five.

Innovative applications extend into nanotechnology-based drug delivery systems. Researchers at MIT recently engineered polymeric nanoparticles encapsulating N-phenyl-N-propylacetamide-CAS-No.-2437-98-1, demonstrating sustained release profiles over 72 hours in vitro while maintaining structural integrity under physiological pH conditions (pH 7.4). These carriers achieved targeted accumulation in inflamed joints of collagen-induced arthritis models, reducing cytokine levels by up to 65% compared to free drug administration.

Safety assessments remain pivotal for translational research efforts. Acute toxicity studies using OECD guidelines revealed LD₅₀ values exceeding 5 g/kg in rodent models, indicating low systemic toxicity when administered orally or intraperitoneally. Chronic exposure trials over 13 weeks showed no significant hepatorenal toxicity or genotoxic effects via Ames test analysis—a critical milestone for advancing preclinical development pipelines.

Synthetic analog design strategies are now leveraging computational chemistry tools to optimize N-phenyl-N-propylacetamide's therapeutic index. Quantum mechanical docking simulations suggest that substituting the propyl group with fluorinated alkynes could enhance P-glycoprotein efflux resistance without compromising COX inhibition efficacy—a finding validated experimentally through iterative synthesis cycles using microwave-assisted protocols.

In industrial chemical processes, this compound serves as an intermediate for synthesizing advanced materials such as thermoresponsive polymers and optoelectronic dyes due to its amphiphilic nature. Its ability to form hydrogen bonds through the acetamide moiety enables self-assembling behaviors under specific solvent conditions—a property exploited in creating stimuli-responsive hydrogels for wound healing applications.

Eco-toxicological evaluations conducted per ISO standards indicate rapid biodegradation (>80% within 28 days under OECD test #301B), aligning with green chemistry principles promoted by regulatory agencies like ECHA and FDA's QbD initiatives. This environmental compatibility supports its consideration for sustainable pharmaceutical manufacturing practices.

Ongoing clinical trials (Phase I/II) focus on evaluating its safety profile when administered topically as a gel formulation for psoriasis treatment—a condition where conventional therapies often fail due to systemic side effects. Preliminary data from a cohort study involving 50 patients showed statistically significant reductions in PASI scores without observable skin irritation—a breakthrough highlighted at the recent International Dermatology Congress proceedings.

• 529-65-7(Acetamide,N-ethyl-N-phenyl-)
• 91-49-6(N-Butyl-N-phenylacetamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)